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Recently, insulin signaling has been highlighted in the pathology of Alzheimer’s disease (AD). 
Although the association between insulin signaling and Tau pathology has been investigated in several studies 
[1-3], the interaction between insulin signaling and Presenilin 1 (PS1), a key molecule of Amyloid 
Apathology, has not been elucidated so far. In this study, we demonstrated that insulin inhibited PS1 
phosphorylation at serine residues (serine 353, 357) via phosphatidylinositol 3-kinase (PI3K)/Akt signal 
pathway and strengthened the trimeric complex of PS1/N-cadherin/-catenin, consequently relocalizing PS1 to 
the cell surface. Since our recent report suggests that PS1/N-cadherin/-catenin complex regulates 




Alzheimer’s disease (AD) is pathologically characterized by amyloid plaques and neurofibrillary tangles 
(NFTs). Amyloid plaques are composed of amyloid peptides (A), which are derived from the amyloid 
precursor protein (APP) via proteolytic cleavage, by γ-secretase [5]. γ-Secretase is an enzymatic complex 
composed of at least four proteins – Presenelin 1 or Presenilin 2 (PS1 or PS2), Nicastrin, Pen 2 and Aph 1 – with  
Presenilin representing the catalytic core [6-8]. On the other hand, NFTs are characterized by the accumulation 
of hyperphosphorylated Tau in neurons [9]. One of the candidates which phosphorylates Tau is Glycogen 
synthase kinase 3  (GSK3) [10]. GSK3 is a serine/threonine protein kinase, originally known to inactivate 
glycogen synthesis. GSK3 an important player in insulin signal cascade [11], is negatively regulated by insulin. 
GSK3 also has a wide variety of substrates, other than glycogen synthase, and is expressed in various 
tissues, with the highest level in the brain. Expression of GSK3 in the brain is considered to be involved in 
3 
abnormal Tau phosphorylation in NFTs [9]. Interestingly, PS1 is also shown to be an unprimed substrate of 
GSK3 [12], phosphorylated at the serine 353 and 357 residues in the loop domain [13]. Therefore, it is 
intriguing to investigate the influence of insulin on the function of PS1 through GSK3, which could connect 
two major pathological hallmarks of AD, namely Aβ and NFTs. 
A potential link between type 2 diabetes and AD has been suggested epidemiologically, clinically and 
experimentally [14-16], indicating the involvement of perturbed insulin signaling in AD pathogenesis. 
Interestingly, insulin and the insulin-sensitizing drug have shown to improve cognitive performance in mouse 
models of AD, as well as in patients with early AD [17-19]. Although many reports suggest that perturbed 
insulin signaling could contribute to the AD pathogenesis, direct interactions between insulin signaling and PS1 
have not been elucidated so far.  
Here, we demonstrate that insulin inhibits PS1 phosphorylation and potentiates PS1/N-cadherin/-catenin 
complex formation at the cell membrane, subsequently redistributing PS1 to the cell surface via PI3K/Akt signal 
pathway. Our findings clearly indicate that PS1 is functionally modulated by insulin signaling, thus providing a 












Material and methods 
 
Plasmid constructs   
The pcDNA3.1-hIR (human Insulin Receptor) construct was a kind gift from Dr. Ikeuchi (Niigata 
University, Japan) [20].  
 
Cell culture and transfection 
For the establishment of cell lines which stably express hIR (Supplemental Fig. 1), SH-SY5Y (derived 
from human neuroblastoma) cells were transfected with pcDNA3.1-hIR, using a TransFectin reagent (Bio-Rad) 
and selected by 300 µg/ml G418 solution (nacalai tesque, Japan). Primary neurons were obtained from the 
cerebral cortices of fetal mice (14-16 days’ gestation) and cultured with Neurobasal medium containing B-27 
supplements and 0.5 mM L-glutamine (all reagents purchased from Invitrogen). After 7 days’ culture, cells 
were used in the experiment.  
 
Antibodies and chemical reagents  
Mouse monoclonal anti-IR was from Neo Markers (Fremont, CA). Rabbit polyclonal anti-Akt, phospho-
Akt (S473), phospho-GSK3 (S9) and mouse monoclonal anti-phospho--catenin antibodies were from Cell 
Signaling Technology. Mouse monoclonal anti-GSK3, N-cadherin and -catenin antibodies were from BD 
Transduction Laboratories. Mouse monoclonal anti-phospho-serine, -actin and A6E10) antibodies were 
from SIGMA. Rabbit polyclonal anti-PS1 NTF, goat polyclonal PS1 CTF and phospho-PS1 (S353/357) 
antibodies were from Santa Cruz. Alexa Fluor 546 anti-mouse IgG and Alexa Fluor 488 anti-goat IgG were 
obtained from Molecular Probes. Insulin solution was from SIGMA and DMSO was from nacalai tesque.  
 
Western blotting and Immunoprecipitation 
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Preparation of protein samples, Western blotting and immunoprecipitation analysis were carried out 
as described previously [21]. 
 
Immunostaining 
Preparation of cell samples and immunostaining analysis was carried out as described previously 
[22]. The samples were examined using a laser confocal scanning microscope, LSM 510 Pascal (Zeiss).  
 
A application 
Synthetic A 1-40, 1-42 and control reverse peptides were obtained from Bachem. Each peptide was 
dissolved in 100% dimethyl sulfoxide (DMSO), at a concentration of 1 mM Aβ solution and aliquots were 
prepared, which were either used fresh or fresh-frozen, and stored at -80°C until use. A solutions were added to 
Opti-MEM, to give a final concentration of 1 µM A 1-40 or 100 nM A 1-42, respectively. Immediately, SH-
SY5Y wt IR cells or primary neurons were pre-incubated in the Acontaining media for 30 min at 37°C. After 
pre-incubation, the cells were stimulated by 50 nM insulin for 30 min, in the presence of A(Schematic 
presentation of this experiment is described in Supplemental Fig. 3A). Characterization of the Aspecies in 
this experiment was analyzed by Tricine-SDS-PAGE (Supplemental Fig. 3B). 
 
Biotinylation of cell surface proteins 
Preparation of cell samples and biotinylation analysis were carried out as described previously [22]. 




All values are given in means ± SE. Comparisons were performed using an unpaired Student’s t-test. For 
comparison of multiparametric analysis, one-way factorial ANOVA followed by post hoc analysis by Fisher’s 

























Insulin signaling inhibited PS1 phosphorylation.   
To investigate the possibility of direct influence of insulin signaling on PS1, we examined whether 
activated PI3K/Akt signaling by insulin inhibits GSK3 activity as well as PS1 phosphorylation. In SH-SY5Y 
wt IR cells, PI3K/Akt pathway was activated by insulin, leading to phosphorylation of GSK3 at serine 9 (Fig. 
1A, 2nd and 4th rows). The inhibition of GSK3 activity was confirmed by the detection of phospho- and total 
levels of -catenin (Fig. 1A, 6th and 7th rows) which is a substrate for GSK3-mediated phosphorylation, since 
GSK3-mediated phosphorylation destabilizes -catenin by promoting proteasomal degradation [23]. 
Accordingly, insulin significantly reduced the level of phosphorylated PS1 in serine 353 and 357 residues (Fig. 
1B, D). This result was confirmed by immunoprecipitation assay (Fig. 1C), and immunostaining with phospho-
specific anti-PS1 antibody clearly demonstrated that insulin treatment markedly reduced PS1 phosphorylation in 
the cells (Fig. 1E-H). 
 
Insulin signaling regulates the subcellular localization of PS1.    
We previously reported that PS1 phosphorylation at serine 353 and 357 affects its localization. 
Phosphorylation at serine 353 and 357 inhibits PS1 binding to N-cadherin/-catenin complex [22]. Since insulin 
signaling inhibited PS1 phosphorylation, we assumed that insulin would in turn redistribute PS1 to the cell 
surface. We examined the effect of insulin on PS1/N-cadherin/-catenin complex by immunoprecipitation assay. 
Insulin treatment dose-dependently increased the binding of PS1 to N-cadherin, as well as to -catenin (Fig. 2A, 
1st and 2nd rows) in SH-SY5Y wt IR cells (relative phosphorylation ratio of p-GSK3β S9/ GSK3β is 
described in Supplemental Fig. 2A). This result was also confirmed in mouse cortex primary neurons (Fig. 2B, 
2nd and 3rd lane). Several downstream pathways are involved in insulin signaling [24, 25]. To verify that GSK3, 
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which is an immediate downstream target of PI3K/Akt pathway, downregulates the association of PS1 and N-
cadherin/-catenin complex, SH-SY5Y wt IR cells were pre-treated with Akt inhibitors (Akt inhibitor IV, X) 
before insulin treatment. Although the treatment with both inhibitors reduced the binding of PS1 to N-
cadherin/-catenin (Fig. 2C), quantitative analysis revealed that Akt inhibitor IV was less effective in 
phosphorylation of GSK3, compared to Akt inhibitor X (Fig. 2D). On the other hand, we demonstrated that 
GSK3 inhibitors strengthened the complex as well as insulin in primary neurons (Fig. 2B, 4th and 5th lanes).  
We have previously reported that physical interaction between PS1 and N-cadherin/-catenin plays an 
important role in cell surface expression of PS1/γ-secretase [22]. Therefore, we examined the expression level of 
cell surface PS1 in the presence of insulin by biotinylation assay. As expected, the cell surface PS1 level in 
insulin-treated cells was higher than that in non-treated ones, confirming that inhibition of GSK3 by insulin 
redistributes PS1 to the cell surface (Fig. 2E, top row, right lane).  
 
A application affects the state of PS1 phosphorylation and its complex formation. 
Several reports have suggested that A can interfere with insulin signaling [26-28]. Since insulin signaling 
could decrease the phosphorylation state of PS1, we treated cells with the medium containing 1 µM Aor 100 
nM A42 and examined the state of PS1/N-cadherin/-catenin complex, as well as PS1 phosphorylation. 
Aspecies in the media were characterized by Tricine-SDS-PAGE (Supplemental Fig. 3B). Both media 
contained similar species including monomer and SDS-resistant oligomers – dimer, trimer, tetramer and 
high molecular weight oligomers. Interestingly, treatment with the medium containing either A40 or A42 
increased the level of phosphorylated PS1 (Fig. 3A, top row, 1st and 2nd lanes), suggesting the up-regulation of 
GSK3 activity (Fig. 3A, 3rd row, 1st and 2nd lanes, Fig. 3B). Moreover, the interaction of PS1/N-cadherin/-
catenin was reduced in neurons treated with A-containing medium (Fig. 3C, 1st and 2nd rows, 2nd and 3rd lanes), 
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compared to reverse A-containing medium (Fig. 3C, 4th lane), indicating that soluble forms of A can enhance 


























Several lines of evidence suggested a potential link between type 2 diabetes and AD. So far, the causal 
relationship between them has been investigated by two distinct approaches: the modulation of Tau 
phosphorylation by GSK3 activity, and A metabolism. In the former, loss of insulin-mediated activation of 
PI3K and subsequent reduction of phosphorylation of Akt and GSK3 are reported to result in a substantial 
increase in levels of phosphorylated Tau in the brains of neuron specific IR knockout mice [3]. Abnormal 
increase in the GSK3 level and activity is actually associated with AD pathophysiology [29]. As for the latter, 
since it is known that A is resolved by Insulin-degrading enzyme (IDE), some researchers hypothesize that 
higher insulin levels in a diabetic condition can induce A accumulation by directly competing with A for IDE, 
thereby limiting A degradation [30, 31]. In spite of mounting evidence that insulin signaling dysfunction or 
insulin resistance are implicated in AD pathophysiology, it still remains largely unknown how two pathological 
hallmarks – Amyloid and Tau –  are causally related to each other via insulin signaling. 
In the present study, we have shown for the first time that insulin-mediated PI3K/Akt signaling decreases 
the phosphorylation of PS1 and enhances PS1/N-cadherin/-catenin interaction via inhibition of GSK3 activity 
(Fig. 1 and 2). As shown in Figure 3D, insulin treatment inactivates GSK3, thereby blocking its activity on PS1 
phosphorylation. This tightens the binding of PS1 to N-cadherin/-catenin complex, which results in 
relocalizing PS1 to the cell surface. In contrast, if this pathway fails to phosphorylate GSK3 due to either 
signaling dysfunction or insulin resistance, GSK3 in an active form tends to phosphorylate PS1, which has less 
ability to form the complex. Since the total -catenin level is affected by the inhibition of GSK3, the increase 
of PS1/-catenin association could be attributed to the elevation of the total -catenin level. However, the total 
N-cadherin level did not change before and after insulin treatment (Fig. 2) thus, leading us to conclude that 
insulin increased the association of PS1 to N-cadherin/-catenin complex. 
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In our study, acute application of A was sufficient to impair the interaction of PS1 and N-cadherin/-
catenin, suggesting the possibility that an ample amount of A could lead to aberrant phosphorylation of PS1 
in AD brains, via reduction of insulin signaling (Fig. 3A-C). The media used in our study contained monomers 
and various SDS-resistant A oligomer species, which were derived from synthetic A (Supplemental Fig. 3). 
Since several reports suggest that A oligomers play an important role on insulin signaling [26-28], we assume 
that the total effect of the A mixture containing these oligomers has an impact on this signaling as well as on 
PS1 phosphorylation. In our recent report, we demonstrated that disruption of PS1/N-cadherin/-catenin 
complex impairs Aproduction but increases theA42/40 ratio [4]. Therefore, we postulate that perturbed 
insulin signaling could play a pivotal role in relocalizing PS1 to the cell surface, which in turn may have an 
impact on A production and A42/40 ratio. 
In relevant literature, neuronal insulin receptor-deficient mice (NIRKO) revealed a great increase in the 
phosphorylation of Tau protein [3]. The decreased phosphorylation of GSK3 observed in these mice results in 
an increased GSK3 activity and may cause the increase in Tau phosphorylation. However, these mice did not 
show any special learning deficits or long-term memory disturbance, suggesting that the mere lack of the IR is 
not sufficient to cause AD-like symptoms. Hence, we hypothesize that molecules downstream from the IR 
might be involved in actual AD brains, with PS1 being a possible target for connecting two seemingly 
independent pathological features – Amyloid and Tau pathologies. Further studies are required to clarify the 
functional interaction between PS1 and insulin signaling in vivo models. Our findings for the first time 
demonstrated that insulin has a potent effect on the localization of PS1 in neuronal cells. Whether these 
phenomena are actually involved in the pathology of sporadic AD cases should be elucidated in future studies. 
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Fig. 1. Insulin signaling inhibits PS1 phosphorylation. 
A. SH-SY5Y wt IR cells were treated with 50 nM insulin for 30 min (right lane). B. Cell lysates were 
immunoblotted with anti-phospho-PS1 S353/357 (p-PS1 S353/357) antibody.  C. Cell lysates were 
immunoprecipitated with monoclonal phospho-serine antibody, followed by immunoblotting with PS1 C-
terminal antibody.  D. The relative phosphorylation ratio of PS1 was quantified from immunoblotting 
assay. (n = 4, p = 0.008, Student’s t-test) Data were means±SE of four independent experiments.  E-H. 
SH-SY5Y wt IR cells with or without insulin treatment for 30 min were immunostained with anti-
phospho-PS1 S353/357 antibody (green). E and G show representative images from cultures in the 
absence or presence of insulin. F and H show high-magnification images of cells contained in the 
rectangles indicated in E and G. Scale bar, 20 μm. 
 
Fig. 2. Insulin signaling regulates the subcellular localization of PS1. 
A. SH-SY5Y wt IR cells were treated with insulin in different concentrations (0 nM, 10 nM, 50 nM). 30 
min after treatment, cell lysates were immunoprecipitated with anti-PS1 N-terminal antibody, followed by 
immunoblotting analysis. Control precipitation was done with normal rabbit IgG (left lane). B. Mouse 
cortex primary neurons were treated with 50 nM insulin for 30 min (3rd lane) or 25 mM LiCl, 10 μM 
GSK3β inhibitor VIII for 4 hrs (4th, 5th lanes). C. SH-SY5Y wt IR cells were pre-incubated with 1 μM Akt 
inhibitor IV or X for 18 hours. DMSO was used as a negative control. After pre-incubation, these cells 
were stimulated by 50 nM insulin for 30 min. D. The effect of Akt inhibitors on the phosphorylation of 
GSK3β S9 was quantitatively analyzed. (n = 3)  E. After treatment with 50 nM insulin for 30 min, cell 
surface proteins were biotinylated and analyzed by immunoblotting assay.   
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Fig. 3. Aβ application affects the state of PS1 phosphorylation and its complex formation. 
A. SH-SY5Y wt IR cells were incubated in the medium containing 1 μM Aβ40 (1
st lane) or 100 nM Aβ42 
(2nd lane) for 30 min, followed by stimulation with 50 nM insulin for 30 min. Reversed sequence peptide 
served as a negative control (3rd lane). Lysates were probed with anti-phospho-PS1 S353/357 and anti-
phospho-GSK3β S9 antibodies.  B. After insulin stimulation, the phosphorylation ratio of GSK3β S9/ 
GSK3β in the presence of Aβ-containing media was quantitatively analyzed (n = 3). C. Mouse cortex 
primary neurons were incubated in the same media conditions, followed by 50 nM insulin stimulation. 
Cell lysates were immunoprecipitated with anti-PS1 N-terminal antibody, followed by immunoblotting 
analysis.  D. Schematic presentation of cellular events caused by insulin. 
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